Horn & Co. Law Offices

Hi-Tech, M&A, IP, Securities Law

Profile Icon

Company's Profile

Established: 2009
Line of Business: Hi-Tech, M&A, IP, Securities Law
Address: 2 Weizmann St., Amot Investments Tower
24 floor, Tel Aviv 6423902
Phone: 972-3-637-8200
Fax: 972-3-637-8201
Email: [email protected]
Website: http://www.hornlaw.co.il
Linkedin: Click to View
Management Icon

Company Executives

  • Yuval Horn, Horn & Co. Law Offices

    Yuval Horn

    Founding Partner

    Horn & Co. Law Offices

    View Profile

    Yuval Horn


    Keren Kanir
    Roy Ribon
    Ohad Mamann
    Orly Sternfeld
    Paz Abercohen
Icon About

About Horn & Co. Law Offices

Horn & Co. is the leading Israeli boutique law firm in the field of hi-tech and life sciences and is unique in its exclusive practice and expertise in this field. The firm’s founder, Yuval Horn, was recognized by the International Who’s Who of Life Sciences Lawyers as a Global Thought Leader (2018, 2019, 2020) and as one of the five leading individuals in the world in life sciences transactions (2013, 2015).

Horn & Co. was founded in September 2009 and is known for its tailored, innovative structures, solutions and advice in complex transactions and situations. Since 1993, we have represented numerous founders, companies, and investors in their transactions in the life science and technology sectors. Recent examples include the representation of Anima Biotech in a license and development agreement with Illy Lilly with an aggregate deal value of over one billion dollars; INX Ltd. in the submission to the SEC of the first prospectus covering the issuance of security tokens; cCAM Biotherapeutics Ltd. In the acquisition by Merck & Co. for $ 605 million, Taboola.com in one of the largest private financing rounds of an Israeli company ($130 million); the formation and representation of Pontifax 6 L.P. and Pontifax Venture Lending, both managed by Pontifax Venture Capital group, Israel’s most prominent life sciences designated investment fund and Diagnostic Robotics Ltd. in its strategic agreements (including the Israeli MOH).

Horn & Co. is the Israeli member of Biolegis (www.biolegis.com), a network of leading European law firms with specific expertise in the representation of biotechnology and medical device companies. The firm’s partners and associates have been recognized by the leading international publications and peers as experts in corporate law, intellectual property and technology transactions and are typically asked to lecture and write about these areas. Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences noting that: “the firm has been active at the ‘top-level’ in the healthcare sector for over 20 years”.

The firm has been consistently selected by Iam Magazine (Intellectual Asset Management) as one of the top 5 “highly recommended” Israeli firms in the field of intellectual property transactions, stating that “Horn & Co is in its element when commercializing intellectual property; its finely-honed business instincts ensure that it can identify the best routes to maximize portfolio value”.” It is one of two firms that boast 3 practitioners as leading in the field. Since 2008 Yuval has been a member and legal advisor of the Institutional Review Board (Helsinki Committee) of the Chaim Sheba Medical Center at Tel-Hashomer. Yuval served as the Co-Chair of the International Bar Association (IBA) Technology Law Committee (2016-2017), is Co-Chair of the IBA Annual World Life Sciences Conference and of the IBA Annual M&A in the Technology Sector Conference.



Horn & Co. has vast experience in the representation of biotechnology, medical device, software, telecommunications, and cleantech companies. The Lawyers at Horn & Co. have participated, during the last 25 years, in numerous transactions involving companies in these sectors, representing companies, founders, academic institutions and funds. The firm provides services for all phases of the company’s lifecycle, in Israel, the US and the EU. The firm advises private and publicly held Israeli and foreign companies in all aspects of their activities from inception, including day-to-day operations and structuring, negotiating, and drafting of commercial and strategic transactions.


With a thorough understanding of the complexities and requirements of technology-based, long-haul development companies, the firm represents clients in all aspects of strategic IP transactions. The firm has extensive expertise in the representation of software companies developing artificial intelligence-based solutions for the medical market. Clients include Zebra Medical, Diagnostic Robotics, Pixcell, Medaware Ltd., Scopiolabs Ltd. and many others.


The firm has a substantial track-record in the representation of purchasers and targets in private and public M&A transactions and is widely experienced in private and public mergers including the involvement and advice in reverse mergers, mergers into publicly - traded shells, asset purchases and share acquisitions. Some recent examples are the representation of Pixcell Ltd. in the agreement with Soulbrain Ltd., Cellect Theraputics, IOptima Ltd. and its shareholders in a multi-stage acquisition transaction with an aggregate deal value of up to $50 million; Eloxx Pharmaceuticals Ltd. in a $38 million financing round and simultaneous entering into an agreement for an acquisition transaction with Sevion Therapeutics, Inc. and the representation of cCam Biotherapeutics Ltd. in its sale to Merck & Co. Inc. with an aggregate deal value of US$605 million.


Horn & Co. regularly advises international and Israeli companies for their relationships with the Israel Innovation Authority and assists in structuring both local and cross-border technology transactions so to adequately conform to applicable regulations and legal requirements. The firm has advised several multinational companies for the incorporation and setting up of businesses in Israel, as well as their relationships with the various governmental branches. Horn & Co. is the Israeli member of TRACE (www.traceinternational.org).


The firm has special experience in registration and issuance of securities of technology companies on US and Israeli securities exchanges, including IPOs, initial coin offerings, follow-on offerings, and PIPEs and is ranked as such in international publications. Recent transactions included Initiation and acting as Israeli counsel of the first submission of a prospectus to the SEC covering security Tokens (by INX Limited), Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $54.1 million private notes exchange agreement, and a $22.5 million private placement of the company’s Secured Convertible Notes, Vascular Biogenics Ltd. in as a series of follow-on offerings on NASDAQ with an aggregate value of over $60 million, the representation of two Israeli publicly traded companies in NASDAQ offerings, and initial public offering on Tel Aviv stock Exchange of Savoreat LTD.


Horn & Co. advises companies, founders, government-funded incubators, private investors, and venture capital funds for their full range of finance transactions, including seed rounds, venture capital funding, venture lending, strategic partner investments, and mergers and acquisitions. Our close acquaintance with both company and investor needs and limitations further enables us to provide a unique view and expertise to transactions. We have advised on the formation of many funds including Pontifax 5 (2018), Pontifax Venture Lending (2019), Pontifax Late Stage (2019), Pontifax 6 (2021) and regularly advise such funds for their relationships with their limited partners.


You may also like